Results 141 to 150 of about 16,895 (259)

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure [PDF]

, 2018
Rishi Trivedi, David J. Polhemus, Zhen Li, Daniel Yoo, Hiroshi Koiwaya, Amy Scarborough, Traci Goodchild, David J. Lefer   +7 more
openalex   +1 more source

Low‐Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real‐World Study in China

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Aims To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results This single‐center observational study (Zhongshan Hospital, China; Oct 2024–Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55 ...
Wenlong Yang, Hui Shi, Rebecca Suchi Chang, Yin Zhang, A. Jixiang, Chunyu Wu, Juying Qian, Junbo Ge, Shuning Zhang, Baohui Xu   +9 more
wiley   +1 more source

Corrigendum to “Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost” [Biochem. Pharmacol. 178 (2020) 114057]

, 2020
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa   +1 more
openalex   +2 more sources

Somatostatin receptor subtypes 1 and 4 redundantly regulate neprilysin, the major amyloid-beta degrading enzyme in brain [PDF]

, 2020
Per Nilsson, Karin Sörgjerd, Naomasa Kakiya, Hiroki Sasaguri, Naoto Watamura, Makoto Shimozawa, Satoshi Tsubuki, Zhulin Zhou, Raúl Loera‐Valencia, Risa Takamura, Misaki Sekiguchi, Aline Petrich, Stefan Schulz, Takashi Saito, Bengt Winblad, Takaomi C. Saido   +15 more
openalex   +1 more source

The Role of Neprilysin and Insulin-Degrading Enzyme in the Etiology of Sporadic Alzheimer's Disease [PDF]

T Morito, Shoko Hashimoto, Risa Takamura, Naoto Watamura, Naomasa Kakiya, Ryo Fujioka, N Mihara, Misaki Sekiguchi, Kaori Watanabe-Iwata, Naoko Kamano, Meng Qi, Yukio Matsuba, Satoshi Tsubuki, Takashi Saito, Nobuhisa Iwata, Hiroki Sasaguri, Takaomi C. Saido   +16 more
openalex   +1 more source

Soluble neprilysin and the translational continuum in cardio-oncology. [PDF]

Cardiooncology
Camilli M, Abbate A.
europepmc   +1 more source

Neprilysin inhibition: a new therapeutic option for type 2 diabetes? [PDF]

, 2019
Nathalie Esser, Sakeneh Zraika
openalex   +1 more source

Soluble neprilysin is associated with myocardial damage and systolic dysfunction in an animal model of doxorubicin-induced cardiotoxicity. [PDF]

Cardiooncology
Sobiborowicz-Sadowska AM, Kamińska K, Sztechman D, Matusik K, Koperski Ł, Borensztejn K, Cudnoch-Jędrzejewska A.   +6 more
europepmc   +1 more source

In Silico Profiling of Pharmacokinetic Properties and Inhibitory Potentials of Chromolaena odorata aqueous leaf extract against Type-2 Diabetes Protein Targets, Neprilysin and Alpha Amylase

Adesegun Adeyemo, Olasunkanmi Awote, Babajide Kayode, Dasola Akorede, Sheu Arowolo, Bisola Omotayo, Oluwasemilore Adeniyi, Oladejo Ahmodu   +7 more
openalex   +1 more source

Retraction: The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1/JNK/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source